Your session is about to expire
← Back to Search
TA-CIN Vaccine for Cervical Cancer
Study Summary
This trial will be testing what dosage of TA-CIN is safe and effective for people who have had HPV16-associated cervical cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have an active or chronic HIV, HBV, or HCV infection.I am a woman who could become pregnant.You have a current autoimmune disease that is active.I have tissue samples available for HPV16 testing.I have or had specific heart, liver, kidney, lung, neurological, or immune conditions.I am fully active or can carry out light work.My organ functions are within normal ranges according to specific tests.I have not had any cancer except for basal cell in the last 5 years.My cancer has not come back in the last 8 weeks.I completed treatment for HPV16 related cervical cancer within the last year.You have taken another experimental medication within the past 28 days before starting the study drug.My cervical cancer is HPV16 positive.I have a weakened immune system or have been on long-term steroids.I have received the HPV vaccine.I haven't had surgery, chemo, or radiation in the last 28 days.I have an immune system disorder or take medication that weakens my immune system.I have wounds that have not yet healed.
Frequently Asked Questions
Are there any other research projects that have been undertaken to evaluate TA-CIN?
"Presently, two research protocols for TA-CIN (arm) are ongoing with none in phase 3. Birmingham, Alabama is the primary site for these investigations; however, three other sites have trials underway utilizing this method of treatment."
Are septuagenarians within the parameters of eligibility for this experiment?
"This clinical trial is searching for participants who have reached the age of majority, but are not yet centenarians."
To what extent could TA-CIN treatment present risks to patients?
"Our analysis at Power yields that TA-CIN (arm) has an overall safety rating of 1 due to its Phase 1 categorization, which indicates limited efficacy and safety data."
Does this trial have any eligibility criteria that must be met to participate?
"Fourteen individuals between the ages of majority and 100, who are currently suffering from a uterine cervical neoplasm, may be accepted into this research. Other qualifications include being compliant with study protocol and having an ECOG Performance Status of 0 to 1 over 8 weeks prior to enrollment."
What is the upper limit for participants in this clinical trial?
"At this time, no more candidates are being sought for this trial. It was originally posted on April 4th 2019 and its information has been most recently updated on July 22nd 2022. If you're still interested in participating in a clinical study of uterine cervical neoplasms, there are 317 trials open at present alongside 2 TA-CIN (arm) studies that are actively enrolling patients."
Are there any current openings for enrolment in this trial?
"This clinical trial has finished recruitment as of July 22, 2022. However, there are still 317 studies for uterine cervical neoplasms and two trials searching patients with TA-CIN (arm)."
Share this study with friends
Copy Link
Messenger